Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailBelgian consensus guidelines for follow-up of women with cervical cytological abnormalities.
Cuvelier, C. A.; Bogers, J. P.; Bourgain, C. et al

in Acta Clinica Belgica (2009), 64(2), 136-43

Detailed reference viewed: 82 (11 ULg)
Full Text
Peer Reviewed
See detailBelgian consensus on metabolic problems associated with atypical antipsychotics
De Nayer, A.; De Hert, M.; Scheen, André ULg et al

in International Journal of Psychiatry in Clinical Practice (2005), 9(2), 130-137

A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation ... [more ▼]

A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic complications occur. In addition, recommendations for counselling of the patient and for the cooperation between the psychiatrist and the general physician or diabetologist, respectively, were provided. [less ▲]

Detailed reference viewed: 42 (1 ULg)
See detailThe Belgian Contribution
Noels-Grötsch, Arlette ULg; Aerts, Conny; Plesseria, Jean-Yves ULg et al

in Fridlund, M.; Baglin, A.; Lochard, J. (Eds.) et al Proceedings of "The CoRoT Mission Pre-Launch Status - Stellar Seismology and Planet Finding" (2006)

Not Available

Detailed reference viewed: 6 (4 ULg)
Full Text
Peer Reviewed
See detailThe Belgian crop growth modelling system (B-CGMS). Contribution of remote sensing.
Eerens, H.; Tychon, Bernard ULg; Dehem, Didier et al

Conference (2000, May 31)

Detailed reference viewed: 8 (2 ULg)
See detailBelgian ecosystems listed in the Habitat Directive
Kuijken, E.; Dufrêne, Marc ULg; Tack, Jurgen

in Peeters, Marc; et al (Eds.) Biodiversity in Belgium (2003)

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailThe Belgian education system after PISA : reform approaches in the French community of Belgium
Lafontaine, Dominique ULg

in Rotte, Ralph (Ed.) International perspectives on education policy (2006)

Detailed reference viewed: 64 (3 ULg)
Full Text
Peer Reviewed
See detailThe belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.
Dresse, Marie-Françoise ULg; Boogaerts, Marc; Vermylen, Christiane et al

in Haematologica (1999), 84(7), 637-42

BACKGROUND AND OBJECTIVE: We reviewed all unrelated donor bone marrow transplants (UDBMT) performed in Belgium up to December 1995 to identify prognostic factors for relapse, transplant-related mortality ... [more ▼]

BACKGROUND AND OBJECTIVE: We reviewed all unrelated donor bone marrow transplants (UDBMT) performed in Belgium up to December 1995 to identify prognostic factors for relapse, transplant-related mortality and survival. DESIGN AND METHODS: A total of 163 UDBMT were performed in 92 males and 71 females aged 1-55 (median 26) years. Patients were transplanted for ALL (n=35), AML (n=34), CML (n=51), other myeloid malignancies (n=14), SAA (n=21) or miscellaneous other diseases (n=8). Most patients had advanced disease; a few patients were in CR1 (n=10) or early chronic phase (CP) of CML (n=5). RESULTS: Overall survival at 5 yrs was 17% (95% confidence interval: 8-32%), but survival was significantly better for patients with non-malignant disorders (55% at 4 yrs). The relapse rate +/-SE was projected to be 40 (28-54)% at 5 yrs, 36 (20-56)% for standard-risk and 68 (43-85)% for high-risk malignancies (p=0.0029). There was no relapse in CML patients transplanted in 1st CP compared to 68% at 4 yrs with more advanced CML (p=0.0033). Grade II-IV acute graft-versus-host disease (aGVHD) occurred in 55% by day 100 and was strongly modulated by age, ranging from 41% in <20-yr-old to 80% in >40-yr-old patients (p=0. 0021). Transplant-related mortality (TRM) was projected to be 72 (52-87)% at 5 yrs including 2 very late deaths from lung fibrosis and secondary cancer. Main causes of death were original disease in 27, secondary malignancy in 2, GVHD in 28, interstitial pneumonia in 21, other infections in 19, and miscellaneous toxic causes in 21 patients. In multivariate analysis, the relapse rate was strongly dependent on the disease status (p=0.0029), TRM being significantly worse with older age (p=0.0049), and overall survival being significantly worse in more advanced disease (p=0.0006), after a second transplant (p=0.0166), in centers of smaller size (p=0.0316) and in older patients (NS). INTERPRETATION AND CONCLUSIONS: Although results have improved somewhat in recent years, UDBMT remains a procedure with a high TRM. UDBMT should be performed in patients with less advanced diseases and in centers with more experience, particularly in the treatment of adult patients. [less ▲]

Detailed reference viewed: 81 (6 ULg)
Full Text
Peer Reviewed
See detailBELGIAN EXPERIENCE OF DCD KIDNEY TRANSPLANTATION
Darius, Tom; Jochmans, Ina; Ledinh, Hieu et al

in Transplant International (2011, September), 24(2), 43-44

Detailed reference viewed: 45 (2 ULg)
Full Text
Peer Reviewed
See detailBelgian experience of robot assisted laparoscopic para – aortic lymphadenectomy for staging of locally advanced cervical carcinoma. A multicentric study.
Fastrez, M; GOFFIN, Frédéric ULg; Vergote, I et al

Poster (2012)

Objectives: FIGO clinical staging, imaging techniques sometimes underestimate extension of locally advanced cervical cancer (LACC). The presence of para-aortic lymph node (LN) metastases in LACC ... [more ▼]

Objectives: FIGO clinical staging, imaging techniques sometimes underestimate extension of locally advanced cervical cancer (LACC). The presence of para-aortic lymph node (LN) metastases in LACC identifies patients with poor prognosis. Laparoscopic para-aortic lymphadenectomy is now proposed as a diagnostic tool. Feasibility and safety of robot assisted laparoscopic para-aortic lymphadenectomy has been reported. We collected data from different Belgian centers to assess its oncological safety and complication rate. Study design: Three centers participated in the study. Thirty seven patients with LACC underwent a pre treatment robot assisted laparoscopic para-aortic lymphadenectomy. Data was prospectively collected. Results: The median number of LN collected was 27.5 (1-54) per patient. Five out of 37 patients had para-aortic node metastasis. The false negative rate for PET CT diagnosing para- aortic node metastasis was 10.8% (4/37). We encountered 2 major intra operative complications (5.4%). Post operative morbidity was low (13.5%). Median follow up was 27 months (95% CI 24–30). Median disease free survival (DFS) was 16 months (95% CI 2.4- 29.6). Patients with negative LN had a median DFS of 24 months (NA) although patients with positive LN had a median DFS of 9 months (95% CI 6.9-11.9). Conclusions: In this series we report that robot assisted laparoscopic para-aortic lymphadencetomy provided the surgeon with useful information to avoid understaging in 10.8% of women with LACC, at the expense of low morbidity (13.5%). Presence of microscopic para-aortic LN metastasis is correlated with shorter DFS. The number of patients with positive LN doesn’t allow us to draw any firm conclusion. [less ▲]

Detailed reference viewed: 17 (0 ULg)
See detailBelgian experience with the Direx Tripter X1.
Andrianne, Robert ULg; Bonnet, Pierre ULg; Similon, Bernard et al

in Lingeman, J.; Newman (Eds.) Shock wave lithotripsy. (1989)

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailBelgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
Ducobu, Jean; Scheen, André ULg; Van Gaal, Luc et al

in Acta Cardiologica (2008), 63(2), 235-48

The demographics of dyslipidaemia have changed towards a more complex atherogenic dyslipidaemia involving increased levels of LDL-C, in particular highly atherogenic small dense particles ... [more ▼]

The demographics of dyslipidaemia have changed towards a more complex atherogenic dyslipidaemia involving increased levels of LDL-C, in particular highly atherogenic small dense particles, hypertriglyceridaemia and low HDL, together with increased levels of markers of cardiovascular inflammation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower cardiovascular morbidity and mortality, but there still remains a high residual risk in dyslipidaemic patients, in particular with metabolic syndrome, type 2 diabetes, or low HDL levels. Fibrates have been shown to reduce plasma triglycerides and increase HDL-C, while improving inflammation, thrombogenesis and endothelial dysfunction. Clinical trials with fibrates have demonstrated their potential to reduce cardiovascular morbidity and mortality too, often through other mechanisms than these of statins. Combination trials of statins with fibrates have shown a more complete improvement of lipid profile and risk markers than each class separately. In contrast with gemfibrozil, fenofibrate does not interact significantly with the pharmacokinetics of statins, and up to now its combination with statins has been shown to have a low risk of muscular side effects or liver toxicity. The ACCORD outcome trial is exploring the possible benefits of the combination of fenofibrate with statins on morbidity and mortality of patients with atherogenic dyslipidaemia. [less ▲]

Detailed reference viewed: 58 (5 ULg)